European officials call for ‘swift and sustained’ action on antimicrobial resistance
Chris Dall, MAToday at 2:36 p.m.
Antimicrobial Stewardship
European health officials are calling for urgent action as a series of new reports shows a mixed picture on antibiotic consumption and antimicrobial resistance (AMR).
5% drop in antibiotic use in people
Among the reports released by the European Centre for Disease Prevention and Control (ECDC) was the annual epidemiologic report on antibiotic consumption in European Union/European Economic Area (EU/EEA) countries, which shows a 5% decline in human antibiotic use compared with the 2019 baseline. There was also a small increase in the proportion of World Health Organization–designated first-line antibiotics being used for common infections—a measure of appropriate antibiotic use.But the drop in antibiotic consumption is far from the EU’s 2030 target of a 20% reduction. And the proportion of first-line antibiotics being consumed (62.5%) is short of the 65% goal by 2030.
The targets were established by EU leaders in 2023 as part of its One Health action plan on AMR, which is estimated to cause at least 35,000 deaths every year on the continent.
“We are still behind with several of the EU’s 2030 targets to counter antimicrobial resistance,” ECDC Director Pamela Rendi-Wagner, MD, said in a press release.
Concern over CRE bloodstream infections
A report on AMR rates in EU/EEA countries shows that bloodstream infections caused by a major drug-resistant pathogen—methicillin-resistant Staphylococcus aureus—fell 19% since 2019. But bloodstream infections caused by third-generation cephalosporin-resistant Escherichia coli and carbapenem-resistant Klebsiella pneumoniae have risen by 16.4% and 72%, respectively, since 2019.ECDC officials are particularly concerned about the rise in infections caused by carbapenem-resistant K pneumoniae, which belongs to a family of pathogens known as carbapenem-resistant Enterobacterales (CRE). CRE have limited treatment options and cause severe and often deadly infections, primarily in hospital patients but also increasingly in people in the community.
“The continued increase of CRE will not only result in negative treatment outcomes for individuals but can also negatively impact the quality and sustainable delivery of healthcare, resulting in a very high risk to patients requiring healthcare in the EU/EEA,” the ECDC said in a rapid risk assessment today on CRE.
ECDC officials say reversing these trends will require “swift and sustained action” by public health authorities, such as improved infection prevention and control measures, antimicrobial stewardship, lab capacity, and strengthened surveillance.
Rendi-Wagner suggested that the use of genomic surveillance, which allows for faster and better assessment of how resistant bacteria spread and evade antibiotics, will help.We are still behind with several of the EU’s 2030 targets to counter antimicrobial resistance.
“This in turn means we can act sooner to stop transmission, more effectively guide treatment decisions, and identify where new antibiotics are most urgently needed,” she said.
AMR ‘not a future threat’ but a current one
Others releasing reports on AMR and antibiotic consumption this week included the Australian Medical Association (AMA), which reported a 4.8% increase in antibiotic prescriptions and 25.2% increase in “critical” antibiotic resistance in Australia in 2024.“Antimicrobial resistance is not a future threat. It is here, it is growing, and it is already having devastating consequences,” AMA President Michael Bonning said in a press release.
A report published by Scottish health agencies showed 9.2% decline in antibiotic use in people from 2024 to 2025, while Sante Publique France reported a 9.6% drop in antibiotic use over the same period, along with a 13.9% decline in antibiotic prescriptions. The sharpest decline in consumption and prescriptions was observed in children ages 5 to 14 years.
But the French report also noted a 310% increase in CRE incidence in French hospitals since 2019.
“Given the ongoing risk of the development of bacteria resistant to antibiotic treatment, it remains important to continue raising awareness among prescribing healthcare professionals and patients about the proper use of antibiotics,” the agency said.